File Download
Supplementary
-
Citations:
- Appears in Collections:
postgraduate thesis: The impact of medical insurance policies on the utilization of anti-cancer drugs in hospitals and the path for Chinese pharmaceutical enterprises to promote the development of innovative drug
| Title | The impact of medical insurance policies on the utilization of anti-cancer drugs in hospitals and the path for Chinese pharmaceutical enterprises to promote the development of innovative drug |
|---|---|
| Authors | |
| Issue Date | 2023 |
| Publisher | The University of Hong Kong (Pokfulam, Hong Kong) |
| Citation | Huang, Y. [黃憗]. (2023). The impact of medical insurance policies on the utilization of anti-cancer drugs in hospitals and the path for Chinese pharmaceutical enterprises to promote the development of innovative drug. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. |
| Abstract | The article is divided into two parts. The first part introduces the management of historical drug and hospital classification in China's medical security system. Through empirical research on the addition of medical insurance drugs through drug price negotiations for the first time by the China Insurance Regulatory Commission and the addition of 17 new anti-tumor drugs, the article discusses the access negotiation of medical insurance drug catalogs and analyzes the impact of medical insurance policies on hospitals. The second part analyzes the characteristics of product innovation in Chinese pharmaceutical companies, introduces the innovation paths and methods of Chinese pharmaceutical companies, and takes the transformation process from raw materials to generic drugs to innovative drugs of the CSPC as an example.
|
| Degree | Doctor of Business Administration |
| Subject | Health insurance - China Antineoplastic agents - China Pharmaceutical industry - China Drug development - China Pharmaceutical technology - China |
| Dept/Program | Business Administration |
| Persistent Identifier | http://hdl.handle.net/10722/341571 |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Huang, Yin | - |
| dc.contributor.author | 黃憗 | - |
| dc.date.accessioned | 2024-03-18T09:56:02Z | - |
| dc.date.available | 2024-03-18T09:56:02Z | - |
| dc.date.issued | 2023 | - |
| dc.identifier.citation | Huang, Y. [黃憗]. (2023). The impact of medical insurance policies on the utilization of anti-cancer drugs in hospitals and the path for Chinese pharmaceutical enterprises to promote the development of innovative drug. (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. | - |
| dc.identifier.uri | http://hdl.handle.net/10722/341571 | - |
| dc.description.abstract | The article is divided into two parts. The first part introduces the management of historical drug and hospital classification in China's medical security system. Through empirical research on the addition of medical insurance drugs through drug price negotiations for the first time by the China Insurance Regulatory Commission and the addition of 17 new anti-tumor drugs, the article discusses the access negotiation of medical insurance drug catalogs and analyzes the impact of medical insurance policies on hospitals. The second part analyzes the characteristics of product innovation in Chinese pharmaceutical companies, introduces the innovation paths and methods of Chinese pharmaceutical companies, and takes the transformation process from raw materials to generic drugs to innovative drugs of the CSPC as an example. | - |
| dc.language | eng | - |
| dc.publisher | The University of Hong Kong (Pokfulam, Hong Kong) | - |
| dc.relation.ispartof | HKU Theses Online (HKUTO) | - |
| dc.rights | The author retains all proprietary rights, (such as patent rights) and the right to use in future works. | - |
| dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
| dc.subject.lcsh | Health insurance - China | - |
| dc.subject.lcsh | Antineoplastic agents - China | - |
| dc.subject.lcsh | Pharmaceutical industry - China | - |
| dc.subject.lcsh | Drug development - China | - |
| dc.subject.lcsh | Pharmaceutical technology - China | - |
| dc.title | The impact of medical insurance policies on the utilization of anti-cancer drugs in hospitals and the path for Chinese pharmaceutical enterprises to promote the development of innovative drug | - |
| dc.type | PG_Thesis | - |
| dc.description.thesisname | Doctor of Business Administration | - |
| dc.description.thesislevel | Doctoral | - |
| dc.description.thesisdiscipline | Business Administration | - |
| dc.description.nature | published_or_final_version | - |
| dc.date.hkucongregation | 2023 | - |
| dc.identifier.mmsid | 991044772707603414 | - |